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Abstract
Objective: Patient chances for cure and palliation for a variety of malignancies may be greatly affected by the care provided
by a treating hospital. We sought to determine the effect of volume and teaching status on patient outcomes for five
gynecologic malignancies: endometrial, cervical, ovarian and vulvar carcinoma and uterine sarcoma.
Methods: The Florida Cancer Data System dataset was queried for all patients undergoing treatment for gynecologic
cancers from 1990–2000.
Results: Overall, 48,981 patients with gynecologic malignancies were identified. Endometrial tumors were the most common,
representing 43.2% of the entire cohort, followed by ovarian cancer (30.9%), cervical cancer (20.8%), vulvar cancer (4.6%), and
uterine sarcoma (0.5%). By univariate analysis, although patients treated at high volume centers (HVC) were significantly
younger, they benefited from an improved short-term (30-day and/or 90-day) survival for cervical, ovarian and endometrial
cancers. Multivariate analysis (MVA), however, failed to demonstrate significant survival benefit for gynecologic cancer patients
treated at teaching facilities (TF) or HVC. Significant prognostic factors at presentation by MVA were age over 65 (HR=2.6,
p,0.01), African-American race (HR=1.36, p,0.01), and advanced stage (regional HR=2.08, p,0.01; advanced HR=3.82,
p,0.01, respectively). Surgery and use of chemotherapy were each significantly associated with improved survival.
Conclusion: No difference in patient survival was observed for any gynecologic malignancy based upon treating hospital
teaching or volume status. Although instances of improved outcomes may occur, overall further regionalization would not
appear to significantly improve patient survival.
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Introduction
To date, studies on the relationship between survival and hospital
volume and teaching status for gynecologic malignancies have
focused primarily on ovarian cancer.[1,2,3,4,5,6,7,8,9,10] A system-
aticreviewofthe effectof specialized careforovarian cancer patients
found no demonstrable benefit by surgeon specialty for earlier stages
ofdisease,butthat surgerybya gynecologiconcologistresulted ina 5
to 8 month median survival benefit for patients with advanced stage
disease.[9,11] Similar findings have been reported by studies
conducted outside the United States.
2 More recently, however, data
from the National Cancer Institutes (NCI) Surveillance Epidemiol-
ogy and End Results (SEER)-linked Medicare database suggests no
benefit for ovarian cancer treated by gynecologists versus gyneco-
logicaloncologist.[12]Aswell,SEER-linkedMedicarehasbeenused
to demonstrate similar outcomes for the use of chemotherapy when
administered by medical oncologists or gynecologic oncologists.[13]
Similar to the more recent studies in ovarian cancer, studies
investigating optimal treatment paradigms for early-stage endome-
trial cancer have found minimal differences in outcomes between
general gynecologists and gynecologic oncologists.[14,15] Studies on
advanced stage endometrial cancer patients, focused on hospital
volume,havesuggestedapotentialsurvivalbenefitforcertainsubsets
of patients, such as the elderly, treated at high-volume cen-
ters.[16,17] To date, the effects of center volume or teaching status
on outcomes of patient with cervical or vulvar cancers or uterine
sarcomas have not been reported in the literature.
In contrast to SEER-linked Medicare data, treatment informa-
tion, including chemotherapy, can be determined for all patients by
treating facility in the Florida Cancer Data System (FCDS), which is
well validated in determining outcome disparities and treatment
differences by center volume or teaching status.[18,19,20,21,22,23]
We therefore examined the FCDS to provide insight into the entire
field of gynecological oncology by examination the major gyneco-
logic malignancies - cervical, ovarian, endometrial, uterine sarcoma,
and vulvar cancers- with thehopeof evaluating theroleoftreatment
facility on patient outcomes.
Methods
The 2007 FCDS data set was used to identify all incident cases
of cervical, ovarian, endometrial and vulvar malignancies and
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2000. A total of 48,981 cases of gynecological cancer were
extracted for analysis (Figure 1). Cases with missing information
for any key variable, duplicate cases, carcinomas in situ, and cases
treated by community physicians independent of the hospital or
ambulatory care center settings were excluded from the univariate
analysis. Incident vulvar carcinoma and uterine sarcoma cases
were analyzed; however, case numbers were too small to establish
a meaningful interpretation of the univariate five-year survival
data. These two gynecological malignancies are described by
demographic, social and clinical characteristics, and are included
in the multivariate logistic regression analysis, which was
performed after combining all types of gynecologic cancers.
Medical facilities were defined as TFs or non-teaching facilities
(NTF) based on recognition as a teaching institution by the
Association of American Medical Colleges (AAMC). There are
currently 11 AAMC-recognized TFs in the state of Florida. The
data from FCDS were tabulated to determine the number of
treated cancers and surgical resections for five gynecologic cancer
types (cervical, ovarian, endometrial, vulvar, and uterine sarcoma)
performed at each institution in the state of Florida during the
study period.
Medical facilities were grouped into tertiles based on number of
surgeries with curative intent performed during the study period.
The upper one-third of institutions was classified as HVC, the
middle one-third as intermediate-volume centers (IVC), and the
lower one-third as low-volume centers (LVC). The definitions of
HVC, IVC, and LVC for cervical, ovarian, endometrial and
vulvar cancers are shown in Figure 1. For uterine sarcoma, HVCs
operated on an average of 5 cases in the 10-year study period,
IVCs operated on an average of 3 cases in the 10-year study
period, and LVCs operated on an average 1 case in the 10-year
study period.
The staging criteria used by the FCDS are consistent with the
Surveillance, Epidemiology, and End Result (SEER, National
Cancer Institute) summary staging and differ from the Interna-
tional Federation of Gynecology and Obstetrics (FIGO) staging
guidelines. In this study, local staging represents disease that does
not extend beyond the primary organ, while those having positive
lymph nodes at the time of resection were classified as having
regional disease. Documentation of distant metastases during the
peri-operative period led to classification of affected patients as
having distant disease.
Statistical computations were performed with SPSS version 15.0
for univariate analyses and the final multivariate regression was
corrected for clustering in facilities using STATA version 8.0.
[24]
The chi-square test was used for group comparisons of categorical
variables and ANOVA was used for group comparisons of
Figure 1. Flow diagram depicting number of incident gynecologic malignancies diagnosed in the state of Florida from 1990–2000.
doi:10.1371/journal.pone.0004049.g001
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specific survival because the FCDS database contains information
only on the primary cause of death. Overall survival was
calculated by subtracting the date of death or date of last contact
from the time of the initial diagnosis. Site-specific thirty-day and
ninety-day survival rates, and five-year survival rates were
calculated using the Kaplan-Meier method. Univariate Cox
proportional hazards regression was used to identify demographic
variables and disease characteristics significantly associated with
survival.
Significant variables from the univariate analysis were included
in the multivariate regression analysis to determine whether facility
characteristics were associated with survival for all gynecologic
malignancies. Data on lymph nodes included the number of lymph
nodes dissected and whether or not lymph nodes were positive for
malignant cells. Due to the co-linearity of these variables, only one
of these variables can be entered as a covariate in the final
multivariate regression model. We chose to enter the variable
depicting number of lymph nodes dissected, as we felt this is a
better marker of the extent of surgical intervention undertaken at
HVCs and TFs compared to LVCs and NTFs. Tumor histology
and stage were covariates entered into the final model to reflect
severity of disease.
Results
Treatment at a teaching facility versus a non-teaching
facility
Patient demographic, social, and clinical
characteristics. Over the ten-year period studied, 10,175
patients with cervical cancer, 15,131 patients with ovarian
cancer, 21,149 patients with endometrial cancer, 2,273 patients
with vulvar cancer, and 253 patients with uterine sarcoma were
identified. Demographics, social and clinical characteristics of the
entire study population treated at TFs and NTFs are summarized
in Table 1. The majority of patients in the cohort were Caucasian
(n=43,653, 89.1%) and non-Hispanic (n=43,901, 89.6%). For
cervical, ovarian, and endometrial cancers, patients were treated
more frequently at NTFs, and those individuals who were treated
at TFs were significantly younger than those treated at NTFs.
Regional and distant disease were more commonly treated at
teaching facilities, whereas gynecologic cancer treated at non-
teaching facilities was more commonly localized disease.
Survival. Kaplan-Meier plots comparing overall survival at
TF and NTF are shown in Figure 2 for (a) cervical cancer, (b)
ovarian cancer, (c) endometrial cancer, (d) uterine sarcoma, and (e)
vulvar cancer. Five-year survival rates for patients diagnosed with
cervical, ovarian and endometrial cancer at TF and NTF are
summarized in Table 2. The five-year survival rates for the cohort
diagnosed with cervical cancer was 61.7%, for the cohort
diagnosed with ovarian cancer was 39.5%, and for the cohort
diagnosed with endometrial cancer was 67.3%. As age increased
for patients diagnosed with all gynecological cancers, five-year
survival rates decreased. For cervical and ovarian cancer, five-year
survival rates by univariate analysis were significantly greater for
patients treated at TFs compared to those treated at NTFs (63.9%
versus 60.9% and 43.9% versus 38.8%; p,0.01, respectively).
Among patients diagnosed with cervical cancer, thirty-day and 90-
day surgical mortality rates were significantly greater at NTFs
compared to TFs (p=0.04).
Treatment at high-volume versus low-volume centers
Patient demographic, social, and clinical characteristics.
Demographics, social and clinical characteristics of the entire study
population treated at HVCs, IVCs, and LVCs are summarized in
Table 1. For all types of cancer, individuals treated at HVCs were
significantly younger than those treated at IVCs or LVCs. For
cervical cancer, IVCs treated more regionally advanced disease
compared to HVCs and LVCs, but HVCs tended to treat patients
with more poorly differentiated cancer. For ovarian cancer, IVCs
treated more regionally advanced disease, but HVCs tended to treat
patientswithmorepoorlydifferentiated cancer.Forendometrialand
vulvar cancers, HVCs treated more regional and distant disease and
tended to treat patient with poorer differentiated cancer. For uterine
sarcomas, IVCs treated more distant stage disease compared to
HVCs and LVCs, but HVCs tended to treat patients with more
poorly differentiated cancer.
Survival. Kaplan-Meier plots comparing overall survival at
HVCs, IVCs, and LVCs are shown in Figure 2 for (f) cervical
cancer, (g) ovarian cancer, (h) endometrial cancer, (i) uterine
sarcoma, and (j) vulvar cancer. Five-year survival rates for patients
diagnosed with cervical, ovarian and endometrial cancer at HVCs,
IVCs and LVCs are summarized in Table 2. For cervical cancer,
five-year survival rates were significantly greater for patients
treated at HVCs compared to those treated at IVCs or LVCs
(64% versus 61.3% versus 59.5%; p,0.01). Thirty-day and ninety-
day surgical mortality rates were significantly lower for patients
treated at HVCs, compared to IVCs or LVCs (p,0.01).
For ovarian cancer, univariate analysis showed that 5-year
survival rates were significantly greater for patients treated at
HVCs compared to those treated at IVCs or LVCs (42.2% versus
40.4% versus 36.2%; p,0.01). Thirty-day and 90-day surgical
mortality rates were significantly lower for patients treated at
HVCs compared to IVCs or LVCs. For endometrial cancer,
univariate analysis demonstrated 5-year survival rates were
significantly greater for patients treated at IVCs compared to
HVCs or LVCs. Thirty-day surgical mortality rates were
significantly lower for patients treated at HVCs compared to
IVCs or LVCs.
Multivariate Analysis. Results of the multivariate analysis
including all five gynecologic malignancies using a Cox regression
model adjusted for clustering effects are summarized in Table 3.
Cox regression models adjusting for clustering effects were also
created separately for each malignancy, with no difference in
survival seen for patients treated at TFs versus NTFs, or HVCs
versus LVCs. An abbreviated regression model for each cancer
type is shown in Table 4. TF status and hospital volume status
were not significant predictors of survival for gynecologic
malignancy. Independent predictors of survival for all
gynecologic malignancies studied in the 10-year period were
diagnosis of ovarian cancer, age .40 years, African-American
race, Medicaid payer status, lymph node examination, tumor
stage, tumor grade, surgical extirpation, chemotherapy treatment,
and lack of radiation therapy.
Compared to patients diagnosed with cervical cancer, ovarian
cancer patients had a 13% increased risk of death over the 10-year
study period. Gynecologic cancer patients aged 41–65 years had a
52% increased risk of death (HR=1.52, p,0.01) and patients
older than 65 years had a 261% increased risk of death
(HR=2.61, p,0.01) compared to patients younger than 40 years.
African-American patients diagnosed with gynecologic malignan-
cies were 36% more likely to die (HR=1.36, p,0.01) in the 10-
year study period compared to Caucasian patients. Medicaid
patients were 29% more likely to die from a gynecologic
malignancy in the 10-year study period (HR=1.29, p,0.01)
compared to privately insured patients. A decreased risk of death
from gynecologic malignancy was found when lymph nodes were
examined compared to when they were not examined. This effect
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PLoS ONE | www.plosone.org 8 January 2009 | Volume 4 | Issue 1 | e4049demonstrated a dose-response relationship, with further risk
reduction when more nodes were examined. Patients with
gynecological cancer were 2.08 times more likely to die when
they had regionally advanced disease (HR=2.08, p,0.01) and
3.82 times more likely to die when they had distant staged disease
(HR=3.82, p,0.01) compared to patients with localized cancer.
More poorly differentiated gynecological cancers portended a
worse prognosis, as an increased risk of death in the 10-year study
period was observed in patients with moderately and poorly
differentiated malignancies compared to patients with well-
differentiated tumors. Patients with a gynecologic malignancy
were at a 57% increased risk of death (HR=1.57, p,0.01) if they
were not treated surgically, compared to patients who were treated
surgically for their cancers. Those patients who did not receive
chemotherapy treatment were at an 8% increased risk of death
(HR=1.08, p,0.01) compared to patients who were treated with
chemotherapy. Patients who did not receive radiation therapy for
their gynecologic malignancy had a 10% decreased risk of death
(HR=0.90, p,0.01) compared to those patients who were treated
with radiation therapy. Stepwise regression models evaluating the
impact of patient characteristics, tumor characteristics, and
treatment for each individual cancer type did not alter the
significance of results (data not shown).
Discussion
It has been demonstrated that the median survival and cure
rates for patients diagnosed with certain malignancies, such as
sarcomas of the trunk and retroperitoneum and cancers arising in
the esophagus and pancreas, are improved when treatment is
provided in specialized centers such as high-volume centers (HVC)
and teaching facilities (TF).[5,19,25,26,27,28,29] Herein we have
attempted to comprehensively determined the impact of both
hospital volume and teaching status for the field of gynecologic
malignancies. To our knowledge this represents the first, and
largest, study providing an overview of the entire field of
gynecological malignancies and the effects of hospital volume
and teaching status to date.
The five malignancies studied represent .98% of all gyneco-
logic malignancies reported to the FCDS database. Multiple Cox
regression analyses were modeled in order to identify any
differences that may have gone undetected. These models
included analysis in which each individual cancer was analyzed -
cervical, endometrial, and ovarian - and one final model in which
all patients with a gynecological malignancy were included.
Patients with uterine sarcomas and vulvar cancers were excluded
from the individual Cox regression modeling because multivariate
analysis of these cancers resulted in no significant predictors of
survival for any of the demographic, clinical or treatment
variables. We suspect inadequate sample size for these specific
cancers as the explanation for these observations.
Overall for all five gynecologic malignancies, and separately for
cervical, endometrial, and ovarian cancer, no demonstrable
benefit for either high volume center or teaching status on patient
survival was observed. We did not have complete data on treating
physician specialty, making it difficult to determine what these
results mean in terms of specific providers. Of note, we were able
to determine that all high volume facilities and teaching hospitals
examined in this study had board-certified gynecologic oncologists
on staff. Many of the low volume centers did not have board-
certified gynecologic oncologists on staff, which suggests that other
medical professionals, likely general obstetrician-gynecologists or
general surgeons, may have delivered care.
There are several possible explanations as to why we fail to find
survival benefits at TFs or HVCs. Gynecologic oncology
fellowship training may be well standardized and patients treated
by these specialists at NTFs or LVCs are provided equivalent care.
In addition, gynecological surgeries - i.e. hysterectomies - are
performed for a number of reasons other than for malignancies.
General obstetrician-gynecologists and general surgeons are often
the providers performing the surgical extirpation for benign
reasons. As such, these providers may get the necessary case
volume to become proficient with these procedures. Thus, while
certain subsets of patients may benefit from treatment by
gynecologic oncologists, we did not find evidence for a significant
survival advantage for patients when they were treated at TFs or
HVCs.
Many studies in ovarian cancer have focused on provider
specialty type (general gynecologist versus gynecologic oncologist),
rather than volumes, specifically. Several studies have found that
treatment at specialized hospitals including high-volume centers
with gynecologic oncologists as providers, are more likely to
include staging procedures, lymph node biopsy, ‘‘optimal’’
debulking and chemotherapy according to guidelines compared
to non-specialized hospitals.[2,3,4,5,6,8,9,13] Many of these
studies were limited by the use of Medicare-linked Surveillance,
Epidemiology, and End Results (SEER) data, which includes only
patients older than 65 years, a variable we have demonstrated is an
independent predictor of worse survival outcomes. Of note,
Woodman et al found no survival advantage for ovarian cancer
patients treated by high-volume operators compared to low
volume-operators; however, they had many fewer cases to analyze
than in our cohort.[10]
In simple regression analysis models, common in many outcome
studies currently in the literature, independence of each individual
patient is assumed. However, outcome studies in which hospital
volume or teaching status is examined, patients treated within the
same facility are not entirely independent. Outcomes of patients
treated at one facility tend to be more similar to one another than
the outcomes of patients treated at an entirely different facility, a
concept known as clustering.[30] As such, studies that do not
account for clustering may exaggerate the statistical significance of
differences in outcome by provider.[24,30]
None of the ovarian cancer volumes studies we could identify in
the literature, to date, have accounted for this particular
phenomenon. Initially, without correction for clustering, a
significant improvement for patients with ovarian cancer treated
at teaching facilities was observed in our dataset. We found
patients treated at a LVC had an 18% increased risk of death
(HR=1.18, p,0.001). Previous studies on ovarian cancer
regionalization have made similar observations. These studies,
however, have not included corrections for the clustering
phenomenon.[1,2,3,4,6,7,8,9,10] After re-analysis, accounting for
clustering in our dataset, we no longer find a survival benefit for
ovarian cancer patients treated at high-volume centers. This
suggests that corrections for clustering is crucial in these types of
Figure 2. Kaplan-Meier survival curves comparing cumulative survival at teaching facilities (TF) and non-teaching facilities (NTF)
for (a) cervical cancer, (b) ovarian cancer, (c) endometrial cancer, (d) uterine sarcoma, and (e) vulvar cancer and at high-volume
centers (HVC), intermediate-volume centers (IVC), and low-volume centers (LVC) for (f) cervical cancer, (g) ovarian cancer, (h)
endometrial cancer, (i) uterine sarcoma, and (j) vulvar cancer.
doi:10.1371/journal.pone.0004049.g002
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without it. As such, the proper interpretation of our dataset
indicates that current chemotherapy and surgical therapies
provided are equivalent at all facilities regardless of teaching
status or volume.
Previous studies on endometrial cancer support our find-
ings.
[14,15] Hoekstra et al[14] found costs and operative times
are increased when general gynecologists participate in the
surgical procedure of patients with early stage endometrial cancer,
but perioperative outcomes were similar when compared to
procedures performed completely by a gynecologic oncologist. In a
small tumor registry, Macdonald et al[15] found that disease-free
and cause-specific survival were equivalent in patients treated by
general gynecologists or gynecologic oncologists for early stage
endometrial carcinoma. These studies limited their sample to early
stage cancers, while we have demonstrated that independent of
stage, treatment at NTFs and LVCs, with presumably fewer
gynecologic oncologists, does not confer a survival disadvantage.
Based on this data, management of early stage endometrial cancer
by a general obstetrician-gynecologist, and perhaps general
surgeons, appears reasonable as there is no evidence of better
outcomes when treated by a gynecologic oncologist. Diaz-Montes
et al[16] found among women $80 years of age with endometrial
cancer, there was a 62% reduction in the risk of 30-day mortality
when they were managed at high-volume hospitals and a 44%
reduction in the risk of 30-day mortality when managed by high-
volume surgeons. Once again, this study did not account for
clustering effects, which may explain our different results.
The FCDS, which currently includes over 2.7 million records, is
a population-based registry of all cancer cases diagnosed and
treated in the state of Florida, which represents about 6% of the
total U.S. population. Although it represents an excellent database
for comparative outcomes analysis, it is not without limitations.
This includes the lack of information in the registry on household
income; however, information on insurance status and race may
serve as an adequate proxy for socioeconomic status. Our dataset
also did not contain information on co-morbidities; therefore, the
data presented reflects overall survival and not cause-specific
survival. Others have demonstrated that inclusion of co-morbid-
ities may not significantly affect results. Eisenkop et al[4] studied
the impact of subspecialty training in gynecologic oncology on the
management of advanced ovarian cancer and reported that the
distribution of perioperative morbidity among ovarian cancer
patients treated by subspecialists versus general obstetrician-
gynecologists was not significantly different between the two
Table 3. Cox Regression Model for Risk of Death.
HR 95% CI p
Cancer
Cervical reference group
Ovarian 1.13 1.07 - 1.20 ,0.01
Endometrial 1.05 0.99 - 1.11 0.13
Uterine sarcoma 0.84 0.61 - 1.16 0.30
Vulvar ND
Hospital Volume
High reference group
Intermediate+Low 0.96 0.91 - 1.03 0.25
Facility
Teaching reference group
Non-Teaching 1.08 0.99 - 1.18 0.08
Age Groups
,40 reference group
41–65 1.52 1.43 - 1.63 ,0.01
.65 2.61 2.41 - 2.83 ,0.01
Race
Caucasian reference group
AA 1.36 1.27 - 1.45 ,0.01
Other 0.84 0.69 - 1.02 0.08
Ethnicity
Hispanic reference group
Non-Hispanic 0.99 0.92 - 1.07 0.84
Primary Payor
insured reference group
non-insured 1.00 0.91 - 1.11 0.98
Medicare 1.03 0.97 - 1.09 0.39
Medicaid 1.29 1.14 - 1.48 ,0.01
Medicare/Medicaid NOS 1.12 1.05 - 1.19 ,0.01
Government 0.81 0.47 - 1.39 0.45
Unknown 1.13 1.08 - 1.18 ,0.01
Lymph Nodes Examined
none examined reference group
1 to 10 0.79 0.73 - 0.85 ,0.01
11 to 20 0.67 0.62 - 0.73 ,0.01
20 to 30 0.62 0.55 - 0.70 ,0.01
.30 0.60 0.49 - 0.75 ,0.01
Unknown 0.95 0.92 - 0.99 0.02
Tumor stage
Localized reference group
Regional 2.08 1.97 - 2.20 ,0.01
Distant 3.82 3.58 - 4.07 ,0.01
Unknown 1.67 1.57 - 1.79 ,0.01
Tumor Grade
Well differentiated reference group
Moderately differentiated 1.47 1.38 - 1.57 ,0.01
Poorly differentiated 1.93 1.81 - 2.05 ,0.01
Undifferentiated 2.21 2.01 - 2.43 ,0.01
Unknown 1.81 1.70 - 1.92 ,0.01
HR 95% CI p
Surgical Extirpation
Yes reference group
No 1.57 1.52 - 1.64 ,0.01
Chemotherapy
Yes reference group
No 1.08 1.03 - 1.13 ,0.01
Radiation
Yes reference group
No 0.90 0.86 - 0.94 ,0.01
AA=African American, HR=hazard ration, ND=not determined.
doi:10.1371/journal.pone.0004049.t003
Table 3. cont.
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PLoS ONE | www.plosone.org 12 January 2009 | Volume 4 | Issue 1 | e4049groups. Furthermore, we submit that ambulatory patients with a
large number of comorbidities are less likely to travel farther to
regionalized centers.[18] Thus, TFs or HVCs may not necessarily
have seen sicker patients and the lack of survival advantage seen at
these facilities may not be related to the overall health of the
patient. Given the fact that we saw no survival advantage in
patients receiving regionalized care after controlling for clustering,
it is likely that comorbidity data would not have altered our results.
Finally, follow-up of patients in the FCDS is passive and
determined generally by report of death certificate to the social
security data set. This may result in under-estimation of patient
deaths by up to 5%.[5,19,25,26,27,28,29]
Studies on cancer treatment in the surgical literature suggest
certain cancers should be treated at HVCs or TFs.[5,19,25,26,
27,28,29] Such studies have resulted in a number of national
initiatives to improve the delivery of cancer care. The American
College of Surgeons, through the development of the National
Surgical Quality Improvement Program (NSQIP), has demon-
strated since 1991 that the systematic collection, analysis and
feedback of risk-adjusted surgical data, including that on hospital
volumes, leads to improved outcomes. Although we were not able
to demonstrate improved survival outcomes for gynecologic
malignancies through regionalized care, the NSQIP initiative of
measuring hospitals surgical outcomes and identifying deficiencies
can be used as a model for gynecologic malignancies as some
differences in regionalized care may exist. Further studies on
regionalization of care may serve to improve survival outcomes,
just as NSQIP has attempted to do for general surgery and its
subspecialties.
In conclusion, we noted improved short-term (30-day and 90-
day) survival for cervical, ovarian and endometrial cancers treated
at HVCs compared to LVCs, but not long-term (overall) survival
for patients with gynecologic malignancies treated at HVCs. After
adjusting for clustering effects, there is not a long-term survival
advantage for gynecologic cancer patients treated at a TFs or
HVCs. These findings suggests further regionalization of gyneco-
logic cancer care will not improve overall patient outcomes.
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